Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $68.19 and last traded at $64.50, with a volume of 392739 shares traded. The stock had previously closed at $64.96.
Gemini Therapeutics Price Performance
The company has a market cap of $2.79 billion, a price-to-earnings ratio of -64.50 and a beta of -0.12. The firm has a 50-day moving average price of $52.44 and a 200 day moving average price of $46.34.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
See Also
- Five stocks we like better than Gemini Therapeutics
- Top Stocks Investing in 5G Technology
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- What Are Dividends? Buy the Best Dividend Stocks
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
